Physician profile
Vu Le
NPI 1912047051
$1,757.18
in general payments reported to CMS, 2019-2025
24 companies · $728 in 2025
The $728 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.66 · 2022: $211 · 2023: $362 · 2024: $426 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $469.18 | 2023-2025 | Entyvio, Gattex |
| Xeris Pharmaceuticals, INC. | $142.40 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Pfizer INC. | $128.84 | 2023-2025 | |
| Abbvie INC. | $117.84 | 2024-2025 | |
| Celgene Corporation | $105.15 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $99.19 | 2024-2025 | Rezdiffra, Resmetirom |
| Biohaven Pharmaceutical Holding Company LTD. | $83.77 | 2022 | |
| Lilly USA, LLC | $58.57 | 2022-2025 | Omvoh |
| Daiichi Sankyo INC. | $54.97 | 2024-2025 | Injectafer |
| Exact Sciences Corporation | $51.53 | 2023 | Cologuard Collection Kit |
| Corcept Therapeutics | $50.61 | 2025 | Korlym |
| Abbott Laboratories | $49.13 | 2022-2023 | Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.71 | 2023-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $42.44 | 2022-2024 | Airsupra |
| Lundbeck LLC | $41.63 | 2022-2024 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $35.65 | 2025 | Voquezna |
| Janssen Biotech, INC. | $35.06 | 2023 | Stelara |
| Olympus America INC. | $30.66 | 2019 | |
| Kyowa Kirin, INC. | $24.59 | 2025 | |
| Sanofi-Aventis U.S. LLC | $23.01 | 2024 | |
| Echosens North America, INC. | $20.63 | 2023 | Fibroscan |
| Neurocrine Biosciences, INC. | $19.09 | 2025 | |
| Alexion Pharmaceuticals, INC. | $14.13 | 2024 | Strensiq |
| Amgen INC. | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vu Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.